4.2 Article

GSNO reductase and β2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol

期刊

PHARMACOGENETICS AND GENOMICS
卷 20, 期 6, 页码 351-358

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FPC.0b013e328337f992

关键词

beta(2)-adrenergic receptor; asthma; bronchodilator responsiveness; gene-gene interaction; GSNO reductase; latinos; pharmacogenetics; polymorphisms

资金

  1. National Institutes of Health [HL078885, HL088133, U19 AI077439, ES015794]
  2. Flight Attendant Medical Research Institute
  3. RWJ Amos Medical Faculty Development [HL086887]
  4. National Institute of Environmental Health Sciences [5U19-ES012496]
  5. American Thoracic Society 'Break-through Opportunities in Lung Disease'
  6. Tobacco-related Disease Research Program New Investigator [15KT-0008]
  7. Ernest S. Bazley
  8. Sandler Center for Basic Research in Asthma
  9. Sandler Family Supporting Foundation
  10. NHLBI [R01HL96673-01]

向作者/读者索取更多资源

Background Short-acting inhaled beta(2)-agonists such as albuterol are used for bronchodilation and are the mainstay of asthma treatment worldwide. There is significant variation in bronchodilator responsiveness to albuterol not only between individuals but also across racial/ethnic groups. The beta(2)-adrenergic receptor (beta(2)AR) is the target for beta(2)-agonist drugs. The enzyme, S-nitrosoglutathione reductase (GSNOR), which regulates levels of the endogenous bronchodilator S-nitrosoglutathione, has been shown to modulate the response to beta(2)-agonists. Objective We hypothesized that there are pharmacogenetic interactions between GSNOR and beta(2)AR gene variants that are associated with variable response to albuterol. Methods We performed family-based analyses to test for association between GSNOR gene variants and asthma and related phenotypes in 609 Puerto Rican and Mexican families with asthma. In addition, we tested these individuals for pharmacogenetic interaction between GSNOR and beta(2)AR gene variants and responsiveness to albuterol using linear regression. Cell transfection experiments were performed to test the potential effect of the GSNOR gene variants. Results Among Puerto Ricans, several GSNOR SNPs and a haplotype in the 3'UTR were significantly associated with increased risk for asthma and lower bronchodilator responsiveness (P = 0.04-0.007). The GSNOR risk haplotype affects expression of GSNOR mRNA and protein, suggesting a gain of function. Furthermore, gene-gene interaction analysis provided evidence of pharmacogenetic interaction between GSNOR and beta(2)AR gene variants and the response to albuterol in Puerto Rican (P = 0.03), Mexican (P = 0.15) and combined Puerto Rican and Mexican asthmatics (P = 0.003). Specifically, GSNOR+17059*beta(2)AR+46 genotype combinations (TG+GG*AG and TG+GG*GG) were associated with lower bronchodilator response. Conclusion Genotyping of GSNOR and beta(2)AR genes may be useful in identifying Latino individuals, who might benefit from adjuvant therapy for refractory asthma. Pharmacogenetics and Genomics 20: 351-358 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据